Abstract
The term medication overuse headache (MOH) was recently introduced by the International Headache Society to describe daily or nearly daily (chronic) headache that occurs after the regular intake (overuse) of any kind of antiheadache or antimigraine drug. Chronic headache is a growing problem throughout the world. It affects up to 3% to 4% of the general population, and 30% to 50% of such headaches are attributed to overuse of antiheadache drugs. This article reviews the literature on the epidemiology, risk factors, and pathophysiology of MOH. It also summarizes current strategies for treating and preventing headache chronicity.
Similar content being viewed by others
References and Recommended Reading
Horton BT, Peters GA: Clinical manifestations of excessive use of ergotamine preparations and management of withdrawal effect: report of 52 cases. Headache 1963, 3:214–226.
Mihatsch MJ: Das Analgetikasyndrom. New York: Thieme; 1986.
Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia 1988, 8(Suppl 7):1–96.
Kaube H, May A, Pfaffenrath V: Sumatriptan. BMJ 1994, 308:1573.
Limmroth V, Kazarawa Z, Fritsche G, Diener HC: Headache after frequent use of serotonin agonists zolmitriptan and naratriptan. Lancet 1999, 353:378.
Limmroth V, Katsarava Z, Fritsche G, et al.: Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002, 59:1011–1014.
International Headache Society: The International Classification of Headache Disorders. Cephalalgia 2004, 24:1–160.
Silberstein SD, Olesen J, Bousser MG, et al.: The International Classification of Headache Disorders, 2nd Edition (ICHD-II)—revision of criteria for 8.2 Medication-overuse headache. Cephalalgia 2005, 25:460–465.
Olesen J, Bousser MG, Diener HC, et al.: New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006, 26:742–746.
Diener HC, Dahlöf CGH: Headache associated with chronic use of substances. In The Headaches, edn 2. Edited by Olesen J, Tfelt-Hansen P, Welch KMA. Philadelphia: Lippincott Williams & Wilkins; 1999 :871–878.
Zeeberg P, Olesen J, Jensen R: Probable medication-overuse headache: the effect of a 2-month drug-free period. Neurology 2006, 66:1894–1898.
Meskunas CA, Tepper SJ, Rapoport AM, et al.: Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache 2006, 46:766–772.
Zidverc-Trajkovic J, Pekmezovic T, Jovanovic Z, et al.: Medication overuse headache: clinical features predicting treatment outcome at 1-year follow-up. Cephalalgia 2007, 27:1219–1225.
Castillo J, Munoz P, Guitera V, Pascual J: Epidemiology of chronic daily headache in the general population. Headache 1999, 39:190–196.
Colas R, Munoz P, Temprano R, et al.: Chronic daily headache with analgesic overuse: epidemiology and impact on quality of life. Neurology 2004, 62:1338–1342.
Lanteri-Minet M, Auray JP, El Hasnaoui A, et al.: Prevalence and description of chronic daily headache in the general population in France. Pain 2003, 102:143–149.
Wang SJ, Fuh JL, Lu SR, et al.: Chronic daily headache in Chinese elderly: prevalence, risk factors, and biannual follow-up. Neurology 2000, 54:314–319.
Rapoport A, Stang P, Gutterman DL, et al.: Analgesic rebound headache in clinical practice: data from a physician survey. Headache 1996, 36:14–19.
Gaist D, Hallas J, Sindrup SH, Gram LF: Is overuse of sumatriptan a problem? A population-based study. Eur J Clin Pharmacol 1996, 3:161–165.
Evers S, Bauer B, Suhr B, et al.: The epidemiology of sumatriptan abuse. In Headache Treatment: Trial Methodology and New Drugs. Edited by Olesen J, Tfelt-Hansen P. Philadelphia: Lippincott Williams & Wilkins; 1997:149–152.
Srikiatkhachorn A, Anthony M: Platelet serotonin in patients with analgesic-induced headache. Cephalalgia 1996, 16:423–426.
Reuter U, Salomone S, Ickstein GW, Waeber C: Effects of chronic sumatriptan and zolmitriptan treatment on 5-HAT receptor expression and function in rats. Cephalalgia 2004, 24:398–407.
Srikiatkhachorn A, Tarasub N, Govitrapong P: Effect of chronic analgesic exposure on the central serotonin system: a possible mechanism of analgesic abuse headache. Headache 2000, 40:343–350.
Park JW, Kim JS, Kim YI, Lee KS: Serotonergic activity contributes to analgesic overuse in chronic tension-type headache. Headache 2005, 45:1229–1235.
Bendtsen L, Jensen R, Olesen J: Decreased pain detection and tolerance thresholds in chronic tension-type headache. Arch Neurol 1996, 53:373–376.
de Tommaso M, Libro G, Guido M, et al.: Heat pain thresholds and cerebral event-related potentials following painful CO2 laser stimulation in chronic tension-type headache. Pain 2003, 104:111–119.
Ayzenberg I, Obermann M, Nyhuis P, et al.: Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures. Cephalalgia 2006, 26:1106–1114.
Fumal A, Laureys S, Di Clemente L, et al.: Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain 2006, 129:543–550.
Lance F, Parkes C, Wilkinson M: Does analgesic abuse cause headache de novo? Headache 1988, 38:61–62.
Bahra A, Walsh M, Menon S, Goadsby PJ: Does chronic daily headache arise de novo in association with regular analgesic use? Headache 2003, 43:179–190.
Zwart JA, Dyb G, Hagen K, et al.: Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT Study. Neurology 2003, 61:160–164.
Katsarava Z, Schneeweiss S, Kurth T, et al.: Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 2004, 62:788–790.
Wiendels NJ, Knuistingh Neven A, Rosendaal FR, et al.: Chronic frequent headache in the general population: prevalence and associated factors. Cephalalgia 2006, 26:1434–1442.
Kavuk I, Weimar C, Kim BT, et al.: One-year prevalence and socio-cultural aspects of chronic headache in Turkish immigrants and German natives. Cephalgia 2006, 26:1177–1181.
Silverman K, Evans SM, Strain EC, Griffiths RR: Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl J Med 1992, 327:1109–1114.
Scher AI, Stewart WF, Lipton RB: Caffeine as a risk factor for chronic daily headache: a population-based study. Neurology 2004, 63:2022–2027.
Zeeberg P, Olesen J, Jensen R: Efficacy of multidisciplinary treatment in a tertiary referral headache centre. Cephalalgia 2005, 25:1159–1167.
Zeeberg P, Olesen J, Jensen R: Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia 2006, 26:1192–1198.
Katsarava Z, Fritsche G, Muessig M, et al.: Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001, 57:1694–1698.
Relja G, Granato A, Bratina A, et al.: Outcome of medication overuse headache after abrupt in-patient withdrawal. Cephalalgia 2006, 26:589–595.
Rossi P, Di Lorenzo C, Faroni J, et al.: Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia 2006, 26:1097–1105.
Krymchantowski AV, Barbosa JS: Prednisone as initial treatment of analgesic-induced daily headache. Cephalalgia 2000, 20:107–113.
Pageler L, Katsarava Z, Diener HC, Limmroth V: Prednisone vs. placebo in withdrawal therapy following medication overuse headache. Cephalalgia 2008, 28:152–156.
Boe MG, Mygland A, Salvesen R: Prednisolone does not reduce withdrawal headache: a randomized, double-blind study. Neurology 2007, 69:26–31.
Mathew NT, Ali S: Valproate in the treatment of persistent chronic daily headache. An open label study. Headache 1991, 31:71–74.
Mei D, Ferraro D, Zelano G, et al.: Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. Clin Neuropharmacol 2006, 29:269–275.
Baumgartner C, Wessely P, Bingol C, et al.: Longterm prognosis of analgesic withdrawal in patients with drug-induced headaches. Headache 1989, 29:510–514.
Diener HC, Dichgans J, Scholz E, et al.: Analgesic-induced chronic headache: long-term results of withdrawal therapy. J Neurol 1989, 236:9–14.
Schnider P, Aull S, Baumgartner C, et al.: Long-term outcome of patients with headache and drug abuse after inpatient withdrawal: five-year follow-up. Cephalalgia 1996, 16:481–485; discussion 461.
Evers S, Suhr B, Bauer B, et al.: A retrospective long-term analysis of the epidemiology and features of drug-induced headache. J Neurol 1999, 246:802–809.
Katsarava Z, Muessig M, Dzagnidze A, et al.: Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia 2005, 25:12–15.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Katsarava, Z., Holle, D. & Diener, HC. Medication overuse headache. Curr Neurol Neurosci Rep 9, 115–119 (2009). https://doi.org/10.1007/s11910-009-0019-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11910-009-0019-4